• Kyodo News

  • SHARE

A pharmaceutical firm’s tardiness in taking safety precautions with a drug linked to more than 120 deaths may have been due to concerns that such moves could have hampered the drug’s approval overseas, it was learned Sunday.

The claim was brought to light when incriminating e-mail correspondence was discovered in October.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW